2023
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.Peer-Reviewed Original ResearchAcute myeloid leukemiaProstate cancerYears of ageAML progressionCancer progressionMyeloid leukemiaStratified survival analysisBiological agingHigh Gleason scoreCox proportional hazardsMarker of progressionProstate cancer progressionPersonalized therapeutic managementMultiple cancer typesAML incidenceOverall survivalPrognostic factorsGleason scoreTherapeutic managementPatient cohortRisk scorePatientsCancer aggressivenessChronological agingProportional hazards
2022
PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER
Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER. Journal Of Urology 2022, 207: e44. DOI: 10.1097/ju.0000000000002518.07.Peer-Reviewed Original Research
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsMarginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsAbrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. Journal Of Clinical Oncology 2021, 39: 77-77. DOI: 10.1200/jco.2020.39.28_suppl.77.Peer-Reviewed Original ResearchProstate cancer-specific survivalU.S. Preventive Services Task ForceSurvival disparitiesUninsured patientsSocioeconomic quintileProstate cancerInsurance statusMarital statusWorse prostate cancer-specific survivalProstate cancer screening recommendationsCox proportional hazards modelDiagnostic time periodsCancer-specific survivalCancer screening recommendationsProportional hazards modelProstate-specific antigenScreening recommendationsSurvival outcomesInsured patientsWorse outcomesHazards modelPatientsBetter outcomesMedian household incomeUninsured individualsTranscription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
Nagaya N, Lee G, Lu Y, Ashizawa T, Nagata M, Kim I, Horie S. Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer. IJU Case Reports 2021, 4: 159-162. PMID: 33977248, PMCID: PMC8088892, DOI: 10.1002/iju5.12272.Peer-Reviewed Original ResearchCastration-resistant prostate cancerTranscription factor 4Prostate cancerTumor cellsAntiandrogen therapyNeuroendocrine differentiationFactor 4Group of patientsTranscription factor 4 expressionMessenger ribonucleic acid expressionFactor 4 expressionRibonucleic acid expressionChemotherapy treatmentPatientsDrug resistanceTherapyCancerChemotherapyCellsExpressionPhysicians
2020
Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture
Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture. Nutrition And Cancer 2020, 73: 2740-2750. PMID: 33319628, PMCID: PMC8670097, DOI: 10.1080/01635581.2020.1857412.Peer-Reviewed Original ResearchConceptsVitamin E mixtureProstate tissue levelsUrine samplesReported adverse eventsDay of surgeryProstate cancer patientsPhase 0 trialsDays of supplementationCancer preventive activityAdverse eventsBlood lossTreatment armsUrine levelsCancer patientsRadical prostatectomyAnimal modelsVitamin EProstate tissueTissue levelsPreventive activitiesProstate levelsSupplementationPatientsProstatectomySurgeryRNA-seq profile of African American men with a clinically localized prostate cancer
Nagaya N, Rosenfeld J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer. Prostate International 2020, 9: 125-131. PMID: 34692584, PMCID: PMC8498718, DOI: 10.1016/j.prnil.2020.11.002.Peer-Reviewed Original ResearchProstate cancer tissuesProstate cancerAfrican American menAA menCA menCancer tissuesPotential genetic risk factorSphingosine-1-phosphate signalingAmerican menExpression levelsGenetic risk factorsIngenuity Pathway AnalysisPathway analysisRNA sequencingPoor prognosisBiochemical recurrenceRadical prostatectomyRisk factorsLow expressionCancerMenCaucasiansSignificant differencesPatientsHigh rateIndividual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasis
2019
A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer
Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters 2019, 19: 476-486. PMID: 31897161, PMCID: PMC6924059, DOI: 10.3892/ol.2019.11123.Peer-Reviewed Original ResearchNon-muscle invasive BCMuscle-invasive BCIndependent prognostic biomarkerInvasive BCPrognostic biomarkerProlonged recurrence-free survivalCancer-specific survivalCancer-specific deathRecurrence-free survivalTissues of patientsBC tissue samplesExpression of mRNAVital clinical significanceMIBC patientsBC prognosisPoor prognosisBladder cancerClinical significanceCancer tumorigenesisUseful markerLow expressionPatientsNovel tumorHigh expressionTissue samplesMP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER
Srivastava* A, Rivera-Nunez Z, Kim S, Sterling J, Farber N, Radadia K, Modi P, Goyal S, Parikh R, Mayer T, Saraiya B, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555316.15591.47.Peer-Reviewed Original ResearchMP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE
Chandra* A, Assassi N, Kwon Y, Farber N, Kim I. MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000556802.43534.0b.Peer-Reviewed Original Research
2018
Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology Seminars And Original Investigations 2018, 37: 86-96. PMID: 30446454, DOI: 10.1016/j.urolonc.2018.10.023.Peer-Reviewed Original ResearchConceptsBladder cancerUrinary cell-free DNACell-free DNAScreening groupHematuria patientsValidation cohortPredictive valueUrine-based markersNegative predictive valuePositive predictive valueGood diagnostic performanceStudy cohortBC patientsUrological cancersNoninvasive biomarkersPatientsScore indexDiagnostic valueHematuriaExpression level ratioLiquid biopsyCohortDiagnostic performanceCancerDS-indexCorrelation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study.
Tabakin A, Sadimin E, Tereshchenko I, Kareddula A, Stein M, Mayer T, Hirshfield K, Kim I, Tischfield J, DiPaola R, Singer E. Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study. 2018, 2 PMID: 30714046, PMCID: PMC6358174.Peer-Reviewed Original ResearchMonths of ADTProstate cancerProstate-specific antigen (PSA) recurrenceSpecific antigen recurrenceAndrogen deprivation therapyAdditional larger studiesProstate cancer patientsLymph node tissueCHD1 deletionDeprivation therapySerum PSAAndrogen deprivationClinical outcomesCancer patientsImmunohistochemical stainsTissue microarrayNode tissueERG fusionLarger studyIndependent correlationTumor suppressor genePilot studyStrong associationPatientsProstatectomyPD29-07 PROGRESS, A WEB-BASED RESOURCE FOR PROSTATE CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS
Diefenbach M, Hudson S, Marziliano A, Fleszar S, Tagai E, Bator A, Chen D, Cox B, Hall S, Kim I, Kim S, Kutikov A, Miyamoto C, Potters L, Reese A, Vira M, Torre G, DeCoster C, Bhat R, Hui S, Miller S. PD29-07 PROGRESS, A WEB-BASED RESOURCE FOR PROSTATE CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS. Journal Of Urology 2018, 199: e570. DOI: 10.1016/j.juro.2018.02.1382.Peer-Reviewed Original Research
2016
Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 74. PMID: 27583246, PMCID: PMC4999522, DOI: 10.3389/fcell.2016.00074.Peer-Reviewed Original ResearchChapter 3 Androgen Receptor
Modi P, Faiena I, Kim I. Chapter 3 Androgen Receptor. 2016, 21-28. DOI: 10.1016/b978-0-12-800077-9.00003-7.Peer-Reviewed Original ResearchAndrogen receptorProstate cancerAndrogen response elementEndocrine therapyAR signalingCastrate resistanceCell cycle progressionNuclear receptorsTranscriptional regulatory effectsReceptorsVariety of mechanismsRegulatory effectsCell deathPrimary targetCastrationCycle progressionCell growthResponse elementSignificant benefitsTarget genesProtein synthesisPatientsTranscription factorsTherapyProstate
2015
Safety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of 751 Patients
Modi P, Kwon Y, Patel N, Dinizo M, Farber N, Zhao P, Salmasi A, Parihar J, Ginsberg S, Ha Y, Kim I. Safety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of 751 Patients. Journal Of Endourology 2015, 29: 1148-1151. PMID: 25891967, DOI: 10.1089/end.2015.0094.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyInsufflation pressureComplication rateHemoglobin levelsOperative timeRadical prostatectomyControl groupShort-term perioperative outcomesPostoperative hemoglobin levelsGlomerular filtration rateMean hemoglobin levelDatabase of patientsHigh complication rateNumber of patientsUse of pneumoperitoneumExperimental groupHigh insufflation pressurePerioperative outcomesRenal functionBlood lossPneumoperitoneum pressureFiltration rateSignificant short-term effectPatientsVenous oozingCorrespondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses
Virtue S, Manne S, Kashy D, Heckman C, Zaider T, Kissane D, Kim I, Lee D, Olekson G. Correspondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses. European Journal Of Cancer Care 2015, 24: 827-839. PMID: 25807856, PMCID: PMC4733598, DOI: 10.1111/ecc.12316.Peer-Reviewed Original ResearchConceptsFruit/vegetable consumptionProstate cancer survivorsCancer survivorsPhysical activityVegetable consumptionHealthy dietGreater patientCouple-based interventionsProstate cancerControl trialHealth behaviorsHealthy behaviorsSurvivorsExercise behaviorBaseline dataPatientsDietSelf-report measuresSpousal relationshipHigher relationship satisfactionSpousesPast yearHigh levelsRelationship satisfactionActivity
2014
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapy